Publications

Targeting RNA Polymerase I in Ewing Sarcoma Treatment

Alexis Bruce, Gavin Anchondo, Rebekah Carter, Sergio Guerrero Pacheco, Hema Sri Kambala, Elizabeth Cortez, Kyra Parker, Le Su

Cancer Science. 2025 Mar 12. doi: 10.1111/cas.70047. Online ahead of print.

The SS18-SSX fusion oncoprotein: friend and foe in targeted therapy for synovial sarcoma

Gavin Anchondo, Kyra Parker, Alexis Bruce, Elizabeth Cortez, Le Su

Oncology Research. 2025 Jan 20. https://doi.org/10.32604/or.2025.060573. First online.

Combination of HDAC and FYN inhibitors in synovial sarcoma treatment

Kyra Parker, Yanfeng Zhang, Gavin Anchondo, Ashlyn Smith, Sergio Guerrero Pacheco, Tadashi Kondo, Le Su

Frontiers in Cell and Developmental Biology. 2024 Jul 9:12:1422452. doi: 10.3389/fcell.2024.1422452.

HDAC2 links ubiquitination to tumor suppression in synovial sarcoma

Christina Cooley, Le Su

Molecular and Cellular Oncology. 2021 Apr 25;8(3):1914291. doi: 10.1080/23723556.2021.1914291.

HDAC2 Regulates Site-Specific Acetylation of MDM2 and Its Ubiquitination Signaling in Tumor Suppression

iScience. 2019 Mar 29:13:43-54. doi: 10.1016/j.isci.2019.02.008.

Inhibition of Methyltransferase Setd7 Allows the In Vitro Expansion of Myogenic Stem Cells with Improved Therapeutic Potential

Cell Stem Cell. 2018 Feb 1;22(2):177-190.e7. doi: 10.1016/j.stem.2017.12.010.

The methyltransferase G9a regulates HoxA9-dependent transcription in AML

Bernhard Lehnertz, Caroline Pabst, Le Su, Michelle Miller, Feng Liu, Lin Yi, Regan Zhang, Jana Krosl, Eric Yung, Jeanette Kirschner, Patty Rosten, Michael Underhill, Jian Jin, Josée Hébert, Guy Sauvageau, Keith Humphries, Fabio Rossi

Genes and Development. 2014 Feb 15;28(4):317-27. doi: 10.1101/gad.236794.113.

Activating transcription factor 2 in mesenchymal tumors

Makoto Endo, Le Su, Torsten Nielsen

Human Pathology. 2014 Feb;45(2):276-84. doi: 10.1016/j.humpath.2013.09.003.

SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas

Kevin Jones, Le Su, Huifeng Jin, Carol Lenz, Lor Randall, Michael Underhill, Torsten Nielsen, Sunil Sharma, Mario R Capecchi

Oncogene. 2013 May 2;32(18):2365-71, 2375.e1-5. doi: 10.1038/onc.2012.247.

Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics

Le Su, Arthur Sampaio, Kevin Jones, Marina Pacheco, Angela Goytain, Shujun Lin, Neal Poulin, Lin Yi, Fabio Rossi, Juergen Kast, Mario Capecchi, Michael Underhill, Torsten Nielsen

Cancer Cell. 2012 Mar 20;21(3):333-47. doi: 10.1016/j.ccr.2012.01.010.

EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor

Le Su, Hongwei Cheng, Arthur Sampaio, Torsten Nielsen, Michael Underhill, Torsten Nielsen

Oncogene. 2010 Jul 29;29(30):4352-61. doi: 10.1038/onc.2010.204.

Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma

Anne Nguyen, Le Su, Belinda Campbell, Neal Poulin, Torsten Nielsen

Sarcoma. 2009:2009:794901. doi: 10.1155/2009/794901.

The BTB/POZ domain of the Arabidopsis disease resistance protein NPR1 interacts with the repression domain of TGA2 to negate its function

Patrick Boyle, Le Su, Amanda Rochon, Heather Shearer, Jhadeswar Murmu, Jee Yan Chu, Pierre Fobert, Charles Després

Plant Cell. 2009 Nov;21(11):3700-13. doi: 10.1105/tpc.109.069971.

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma

Joanna Lubieniecka, Diederik de Bruijn, Le Su, Anke van Dijk, Subbaya Subramanian, Matt van de Rijn, Neal Poulin, Ad Geurts van Kessel, Torsten Nielsen

Cancer Research. 2008 Jun 1;68(11):4303-10. doi: 10.1158/0008-5472.CAN-08-0092.